Blockers of the renin–angiotensin–aldosterone system (RAAS), that is, renin inhibitors,
angiotensin (Ang)-converting enzyme (ACE) inhibitors, Ang II type 1 receptor antagonists, and …

Significance: Angiogenesis inhibition with humanized antibodies targeting vascular endothelial
growth factor (VEGF) or orally active small tyrosine kinase inhibitors targeting VEGF …

Inhibition of angiogenesis with humanized monoclonal antibodies to vascular endothelial
growth factor (VEGF) or with tyrosine kinase inhibitors targeting VEGF receptors has become …

Angiogenesis inhibition with sunitinib, a multitarget tyrosine kinase inhibitor of the vascular
endothelial growth factor receptor, is associated with hypertension and cardiac toxicity, of …

Angiogenesis inhibition is an established treatment for several tumor types. Unfortunately,
this therapy is associated with adverse effects, including hypertension and renal toxicity, …

Context: Anticancer treatment with the tyrosine kinase inhibitor sunitinib causes thyroid
dysfunction. Objective: Our objective was to investigate the time course and underlying …

Common adverse effects of angiogenesis inhibition are hypertension and renal injury. To
determine the most optimal way to prevent these adverse effects and to explore their …

Aims Our aim was to determine the contribution of the three angiotensin (Ang) II receptor
subtypes (AT 1a , AT 1b , AT 2 ) to coronary responsiveness, cardiac histopathology, and tissue …

Blockers of the renin–angiotensin system (RAS) are widely used for the treatment of cardiovascular
and renal diseases. It is generally assumed that the beneficial effects of these drugs …

Angiogenesis inhibition by blocking vascular endothelial growth factor (VEGF)-mediated
signalling with monoclonal antibodies or tyrosine kinase inhibitors has become an established …